Treacher Collins Syndrome
Summary
Clinical characteristics.
Treacher Collins syndrome (TCS) is characterized by bilateral and symmetric downslanting palpebral fissures, malar hypoplasia, micrognathia, and external ear abnormalities. Hypoplasia of the zygomatic bones and mandible can cause significant feeding and respiratory difficulties. About 40%-50% of individuals have conductive hearing loss attributed most commonly to malformation of the ossicles and hypoplasia of the middle ear cavities. Inner ear structures tend to be normal. Other, less common abnormalities include cleft palate and unilateral or bilateral choanal stenosis or atresia. Typically intellect is normal.
Diagnosis/testing.
The diagnosis of TCS is established in about 97% of probands by detection of a heterozygous (autosomal dominant) pathogenic variant in TCOF1, POLR1D, or POLR1B or biallelic (autosomal recessive) pathogenic variants in POLR1C or POLR1D using molecular genetic testing and in about 3% of probands by clinical findings when molecular genetic testing has not been performed or does not identify pathogenic variants in one of the known genes.
Management.
Treatment of manifestations: Treatment should be tailored to the specific needs of each individual, preferably by a multidisciplinary craniofacial management team. Neonates with airway issues may require special positioning or tracheostomy to facilitate ventilation. Hearing loss is treated with bone conduction amplification, speech therapy, and educational intervention. Craniofacial reconstruction is often necessary. Cleft palate repair (if needed) occurs at about age one year; zygomatic and orbital reconstruction at about age five to seven years; and bilateral microtia and/or narrow ear canal reconstruction after age six years. The age of maxillomandibular reconstruction varies by severity; orthognathic therapies are typically before age 16 years.
Genetic counseling.
Treacher Collins syndrome (TCS) can be inherited in an autosomal dominant or autosomal recessive manner.
- Autosomal dominant TCS. About 55%-61% of probands have the disorder as the result of a de novo TCOF1, POLR1D, or POLR1B pathogenic variant. Each child of an individual with TCS has a 50% chance of inheriting the pathogenic variant.
- Autosomal recessive TCS. The parents of a child with autosomal recessive TCS are obligate heterozygotes (i.e., carriers of one POLR1C or POLR1D pathogenic variant). At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
Once the TCS-related pathogenic variant(s) have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.
Diagnosis
Suggestive Findings
Treacher Collins syndrome (TCS) should be suspected in individuals with the following craniofacial features (see Teber et al [2004], Figure 2; Trainor et al [2009], Figure 2; Dauwerse et al [2011], Figure 1; and Vincent et al [2016], Figure 1), hearing loss, and radiographic findings.
Craniofacial features
- Midface hypoplasia with a bilaterally symmetric convex facial profile, prominent nose, and characteristic downward slant of the eyes secondary to hypoplasia of the zygomatic arch and lateral aspects of the orbits
- Micrognathia and retrognathia with variable effects on the temporomandibular joints and jaw muscles
- External ear abnormalities including absent, small, malformed, and/or rotated ears, and atresia or stenosis of the external auditory canals
- Lower eyelid abnormalities including the following:
- Coloboma (notching)
- Sparse, partially absent, or totally absent lashes and tear ducts
Preauricular hair displacement, in which hair growth extends in front of the ear to the lateral cheekbones
Conductive hearing loss is attributed most commonly to ankylosis, hypoplasia, or absence of the ossicles and hypoplasia of the middle ear cavities. Inner ear structures are typically normal.
Radiographic features
- Hypoplasia or aplasia (discontinuity) of the zygomatic arch, detected by occipitomental radiographs (Waters' view) [Posnick & Ruiz 2000]
- Mandibular retrognathia, detected by orthopantogram [Posnick & Ruiz 2000]
Establishing the Diagnosis
The diagnosis of TCS is established in about 97% of probands by detection of a heterozygous (autosomal dominant) pathogenic variant in TCOF1, POLR1D, or POLR1B or biallelic (autosomal recessive) pathogenic variants in POLR1C or POLR1D using molecular genetic testing (Table 1) and in about 3% of probands by clinical findings when molecular genetic testing has not been performed or does not identify pathogenic variants in one of the known genes.
Molecular Diagnosis of TCS
Molecular genetic testing approaches can include a combination of gene-targeted testing (concurrent or serial single-gene testing, multigene panel) and comprehensive genomic testing (chromosomal microarray analysis, exome sequencing, exome array, genome sequencing).
- Serial single-gene testing. Sequence analysis detects small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, whole-exon or whole-gene deletions/duplications are not detected. Perform sequence analysis of TCOF1 first, since the majority of individuals with TCS will have a pathogenic variant in this gene (Table 1). If no pathogenic variant is found in TCOF1, perform sequence analysis of POLR1B, POLR1C, and POLR1D, and gene-targeted deletion/duplication analysis to detect intragenic deletions or duplications for TCOF1 and POLR1D.
- Chromosomal microarray analysis (CMA), which uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including TCOF1 as well as surrounding genes) that cannot be detected by sequence analysis, could be considered when an individual with clinical features of TCS also has intellectual disability.
- A multigene panel that includes TCOF1, POLR1B, POLR1C, and POLR1D, and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis or deletion/duplication analysis. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
- Comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is an option when TCOF1 sequence analysis does not reveal a pathogenic variant. Exome sequencing could be considered to assess variants in POLR1B, POLR1C, POLR1D, and the rest of the genome. If exome sequencing is not diagnostic, exome array (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis. Genome sequencing is also possible.For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
Table 1.
Gene 1, 2 | Proportion of TCS Attributed to Pathogenic Variants in Gene | MOI | Proportion of Pathogenic Variants 3 Detectable by Method | ||
---|---|---|---|---|---|
Sequence analysis 4 | Gene-targeted deletion/duplication analysis 5 | CMA 6 | |||
POLR1B | 1.3% 7 | AD (3/3) 7 | 5/5 7 | No multiexon or whole-gene deletions / duplications reported | |
POLR1C | 1.2% 8 | AR (3/3) 8 | 3/3 8 | No multiexon or whole-gene deletions / duplications reported | No whole-gene deletions / duplications reported |
POLR1D | 6% 9 | AD (28/31) 10 | 28/31 10, 11 | 3/31 10 | |
AR (3/31) 11 | |||||
TCOF1 | 63%-93% 12 86% w/typical features 13 | AD | >97% 12 | 14 deletions reported 14 | 2 large deletions 14 |
Unknown | 3% 7, 9 | NA |
- 1.
Genes are listed in alphabetic order.
- 2.
See Table A. Genes and Databases for chromosome locus and protein.
- 3.
See Molecular Genetics for information on allelic variants detected in this gene.
- 4.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 5.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (e.g., those described by Vincent et al [2014]) may not be detected by these methods.
- 6.
Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including TCOF1 or POLR1D) that cannot be detected by sequence analysis. The ability to determine the size of the deletion/duplication depends on the type of microarray used and the density of probes in the 5q32-q33.1 or 13q12.2 regions.
- 7.
Sanchez et al [2020] reported three new missense POLR1B variants in five families with classic TCS clinical signs and lacking genetic variants in TCOF1, POLR1C, and POLR1D. Three of the individuals had de novo variants; one family showed autosomal dominant inheritance in a mother and daughter; one family showed mosaicism in the father of the affected individual. The mosaic father presented with mild features characteristic of TCS.
- 8.
Three homozygous probands [Dauwerse et al 2011]
- 9.
Individuals with typical clinical signs of TCS who do not have pathogenic variants in TCOF1, POLR1B, POLR1C, or POLR1D [Vincent et al 2016, Sanchez et al 2020]
- 10.
Dauwerse et al [2011], Vincent et al [2016]
- 11.
The same homozygous variant, c.163C>G (p.Leu55Val), was reported in three families [Schaefer et al 2014, Vincent et al 2016].
- 12.
The majority of individuals with TCS are heterozygous for a pathogenic variant in TCOF1. Differences in reported percentages could reflect variations in populations or clinical criteria for typical TCS. Splendore et al [2000] reported 93% sensitivity (26/28 individuals with clinical diagnosis of TCS); Teber et al [2004] reported 78% sensitivity (8/36 individuals who had unequivocal features of TCS had no pathogenic variant in TCOF1); Bowman et al [2012] identified a TCOF1 pathogenic variant in 70.6% (84/119) of unrelated individuals with a strong suspicion of TCS; Vincent et al [2016] reported 63% sensitivity among individuals (92/146) with typical and atypical clinical features of TCS.
- 13.
Vincent et al [2016] reported 86% (72/84) of those with typical TCS features had a TCOF1 variant.
- 14.
Reported deletions range from single exon to whole gene [Beygo et al 2012, Bowman et al 2012, Vincent et al 2014, Vincent et al 2016]. Although >97% of reported cases had a pathogenic variant detectable by sequencing, Bowman et al [2012] reported 5% of cases (5/92) with a large deletion; therefore, the rate of large deletions may be higher than current data suggest.
Clinical Diagnosis of TCS
TCS is generally characterized by bilaterally symmetric abnormalities of the facial and mandibular structures; downward-slanting palpebral fissures, and hypoplasia of the zygomatic complex and mandible are almost always evident (see Suggestive Findings and Clinical Description).
Clinical Characteristics
Clinical Description
Treacher Collins syndrome (TCS) is characterized by facial features of bilateral and symmetric downslanting palpebral fissures, malar hypoplasia, and micrognathia. The hypoplasia of the zygomatic bones and mandible can cause significant feeding and respiratory difficulties. Ear abnormalities are associated with conductive hearing loss. Other, less common abnormalities include cleft palate and unilateral or bilateral choanal stenosis or atresia.
Significant inter- and intrafamilial clinical variability is common in TCS [Posnick & Ruiz 2000, Teber et al 2004]. While some individuals may be so mildly affected as to go undiagnosed (Figure 1), others can have severe facial involvement and life-threatening airway compromise [Trainor & Andrews 2013].
Figure 1.
Classic features of TCS are bilaterally symmetric and evident at birth (Table 2). Table 3 presents a scoring system to rate the severity of clinical findings.
Table 2.
Classic Feature | % (n) of Affected Individuals w/Feature | |||
---|---|---|---|---|
Vincent et al [2016] | Teber et al [2004] | Splendore et al [2000] | ||
Very frequent | Downward-slanting palpebral fissures | 99% (76/77) | 100% (35/35) | 89% |
Malar hypoplasia / hypoplasia of zygomatic complex | 97% (76/78) | 97% (34/35) | 81% | |
Conductive hearing loss | 92% (69/75) | 83% (25/30) | ||
Mandibular hypoplasia / micrognathia | 88% (69/78) | 91% (32/35) | 78% | |
Frequent | Atresia of external ear canal | 71% (46/65) | 68% (23/34) | |
Microtia | 70% (55/79) | 71% (25/35) | 77% | |
Coloboma (notching) of the lower lid | 63% (46/73) | 54% (19/35) | 69% | |
Delayed speech development | 57% (16/28) | |||
Asymmetry | 52% (34/65) | |||
Preauricular hair displacement | 49% (25/51) | 24% (8/33) | ||
Rare | Nasogastric tube or gastrostomy in neonates | 28% (17/60) | ||
Cleft palate | 21% (15/70) | 33% (11/33) | 28% | |
Intubation or tracheostomy in neonates | 18% (12/65) | 12% (4/34) | ||
Choanal stenosis/atresia | 13% (8/64) | 25% (8/32) | ||
Cardiac malformation | 11% (7/65) | |||
Very rare | Rachis malformation | 7% (3/42) | ||
Renal malformation | 4% (2/50) | |||
Microcephaly | 3% (2/66) | |||
Intellectual disability / delayed motor development | 1.7% (1/58) | 10% (3/30) | ||
Limb anomaly | 1.5% (1/67) |
Table 3.
Feature | Points Assigned 1 | |
---|---|---|
Teber et al [2004] | Vincent et al [2016] | |
Downward-slanting palpebral fissures | 2 | 1 |
Malar hypoplasia / hypoplasia of zygomatic complex | 2 | 1 |
Conductive hearing loss | 1 | 2 |
Mandibular hypoplasia / micrognathia | 2 | 1 |
Atresia of external ear canal | 1 | 1 |
Microtia | 2 | 1 |
Coloboma (notching) of the lower lid | 2 | 1 |
Delayed speech development | Not assigned | Not assigned |
Asymmetry | Not assigned | 1 |
Preauricular hair displacement | 1 | 1 |
Nasogastric tube or gastrostomy in neonates | Not assigned | 2 |
Cleft palate | 1 | 1 |
Intubation or tracheostomy in neonates | 1 | 2 |
Choanal stenosis/atresia |